|1.||Aboagye, Eric O: 9 articles (01/2014 - 03/2005)|
|2.||Krohn, Kenneth A: 8 articles (05/2015 - 05/2004)|
|3.||Buck, Andreas K: 7 articles (07/2014 - 09/2003)|
|4.||Nishiyama, Yoshihiro: 6 articles (05/2015 - 10/2007)|
|5.||Yamamoto, Yuka: 6 articles (05/2015 - 10/2007)|
|6.||Schwartz, Jeffrey L: 5 articles (05/2015 - 05/2004)|
|7.||Jacobs, Andreas H: 5 articles (01/2014 - 12/2005)|
|8.||Elsinga, Philip H: 5 articles (01/2011 - 02/2004)|
|9.||Jager, Pieter L: 5 articles (12/2009 - 02/2004)|
|10.||Grierson, John R: 5 articles (01/2007 - 05/2004)|
11/01/2005 - "The rate constant for the metabolite-corrected net irreversible uptake of [18F]FLT (Ki) ranged from 0.6 to 10.4 x 10(-4) and from 0 to 0.6 x 10(-4) mL plasma cleared/s/mL tissue in tumor (29 regions, 15 patients) and normal tissues, respectively. "
07/01/2014 - "Further studies are needed to determine the optimal timing of 18F-FLT PET/CT imaging in the course of cancer therapies or at the conclusion of therapy."
01/01/2012 - "The aim of the study was to use [18F]FLT positron emission tomography (PET) to study non-invasively early anti-proliferative effects of the experimental chemotherapeutic agent TP202377 in both sensitive and resistant tumors. "
02/01/2005 - "Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies."
10/01/2004 - "In the biodistribution study, considerable uptake of 18F-FLT was observed in both tumor types. "
|2.||Glioblastoma (Glioblastoma Multiforme)
10/01/2014 - "Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme."
01/01/2012 - "Cell uptake of 18F-FLT and 125I-IdUrd was studied in 2 human breast, 2 colon cancer and 2 glioblastoma lines. "
12/01/2005 - "Uptake ratios of 18F-FLT were higher in glioblastomas than in astrocytomas (P<0.01). "
01/01/2013 - "Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging."
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|4.||Carcinoid Tumor (Carcinoid)
|5.||Breast Neoplasms (Breast Cancer)
10/01/2012 - "She entered a clinical 18F-FLT PET trial in our hospital to differentiate malignant breast tumors from benign ones. "
01/01/2013 - "Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT."
01/01/2012 - "FdUrd enhanced 18F-FLT cellular inflow in 2 breast cancer lines by factors of 1.8 and 1.6, respectively, while outflow persisted at a slightly lower rate. "
09/01/2007 - "3'-deoxy-3'-[18F]fluorothymidine positron emission tomography ([18F]FLT-PET) has been developed for imaging cell proliferation and findings correlate strongly with the Ki-67 labelling index in breast cancer. "
11/01/2005 - "We conclude that [18F]FLT-positron emission tomography is a promising clinical tool for imaging cellular proliferation in breast cancer, and is most predictive when analyzed by graphical and spectral methods."
|1.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|7.||Biological Markers (Surrogate Marker)
|10.||Deoxyglucose (2 Deoxy D glucose)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)